We deliver integrated, end-to-end turnkey solutions dedicated to full-process mRNA vaccine commercial production, covering facility layout design, process engineering, core equipment integration, utility system deployment, GMP validation and complete project handover. Tailored for the unique low-shear, temperature-sensitive and high-sterility requirements of nucleic acid vaccine manufacturing, our one-stop solution covers plasmid amplification, in vitro transcription, mRNA purification, LNP encapsulation, sterile formulation and fill-finish workflows. Eliminating fragmented construction and process inconsistency pain points, our standardized industrial framework supports stable batch manufacturing for clinical trial batches and large-scale commercial mRNA vaccine production.
Our turnkey production line adopts process-driven modular layout optimized for the biochemical characteristics of mRNA materials and LNP formulation systems. The upstream plasmid and mRNA synthesis module supports high-purity template amplification and efficient in vitro transcription with strict nuclease-free environmental control. The core LNP preparation unit integrates low-shear mixing and high-precision microfluidic encapsulation technologies to ensure uniform nanoparticle size distribution and high mRNA encapsulation efficiency. The full closed-loop production process minimizes manual intervention, avoids mRNA degradation and LNP agglomeration, and achieves stable physicochemical indicators and superior batch-to-batch consistency for finished vaccine products.
All facility layouts, process equipment, cleanroom environments and supporting utility systems strictly comply with FDA, EMA and global cGMP guidelines for novel nucleic acid vaccine products. We deploy fully validated WFI, pure steam and oil-free compressed air systems to maintain long-term nuclease-free, low-temperature and high-aseptic production conditions. The entire production line supports standardized CIP/SIP sterilization and full-process data traceability. We provide complete DQ, IQ, OQ and PQ validation packages, technical documents and material certification, ensuring full audit readiness and seamless regulatory approval for mRNA vaccine industrial projects.
Engineered for product iteration and capacity expansion in the mRNA vaccine industry, our turnkey production line features flexible modular and expandable design. It supports seamless scale-up from pilot process verification and small-batch clinical production to large-scale commercial manufacturing, and adapts to iterative updates of new vaccine strains and formulation formulas. Highly automated intelligent operation reduces operational errors and comprehensive manufacturing costs while shortening project delivery cycles and product time-to-market. We deliver stable, compliant and future-proof industrial infrastructure to accelerate the standardized commercialization and large-scale market promotion of mRNA vaccines.
